The purpose of this study is to:

* evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity
* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity
* evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity

A Study to Evaluate ALN-2232 in Participants With Obesity

Obesity

METABOLIC

Placebo

ALN-2232

Tirzepatide

Clinical Trial Site

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-2232 as Monotherapy and Co-initiated With Tirzepatide in Adult Participants With Obesity

Measured by dual x-ray absorptiometry (DXA)

Participants will be administered a single dose of ALN-2232

Participants will be administered a single dose of placebo

Participants will be administered multiple doses of ALN-2232

Participants will be administered multiple doses of placebo

Participants will be administered multiple doses of tirzepatide once weekly